Modified SALT Score for Alopecia Areata
Modified SALT Score for Assessment of Alopecia Areata
1 other identifier
interventional
20
1 country
1
Brief Summary
Patchy Alopecia areata was treated by intralesional steroids for 3 months and was evaluated by percentage of involvement, mSALT score and dermoscopy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_4
Started Jan 2020
Shorter than P25 for phase_4
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2020
CompletedFirst Submitted
Initial submission to the registry
May 29, 2020
CompletedFirst Posted
Study publicly available on registry
June 2, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2020
CompletedJune 2, 2020
May 1, 2020
6 months
May 29, 2020
May 29, 2020
Conditions
Outcome Measures
Primary Outcomes (2)
Percentage involvement
Degree of severity expressed as a percentage
6months to 1 year
Modified Severity of Alopecia Tool (mSALT) score
New Score calculating severity (hair density) and area as a number minimum value is 0 and maximum value is 105 the higher the number of the score the worse the affection
6 months to 1 year
Study Arms (2)
Intralesional Steroids
ACTIVE COMPARATORControl
PLACEBO COMPARATORInterventions
intralesional injection of triamcinolone acetonide every 2 weeks for 6 sessions
Eligibility Criteria
You may qualify if:
- localized scalp AA ( 2 patches and ≤50% scalp involvement , duration more than 6 months) • patients who did not receive any medication for at least 2 months before starting the study and those who agreed to join the study and signed written consent.
You may not qualify if:
- pregnant, and lactating females
- Alopecia totalis or universalis or ophiasis or cicatritial alopecia
- Usage of systemic treatment of alopecia areata 2 months prior to the study.
- Any scalp lesion within the treated area
- Bleeding diathesis, severe anemia or platelet disorders
- Medical conditions such as autoimmune diseases.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Kasr El Ainy university hospital, Faulty of medicine,Cairo university
Cairo, Egypt
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
May 29, 2020
First Posted
June 2, 2020
Study Start
January 1, 2020
Primary Completion
July 1, 2020
Study Completion
August 1, 2020
Last Updated
June 2, 2020
Record last verified: 2020-05